About Bioline  All Journals  Testimonials  Membership  News

Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
ISSN: 1596-5996
EISSN: 1596-5996
Vol. 13, No. 10, 2014, pp. 1745-1747
Bioline Code: pr14241
Full paper language: English
Document type: Case Report
Document available free of charge

Tropical Journal of Pharmaceutical Research, Vol. 13, No. 10, 2014, pp. 1745-1747

 en Cholestatic Hepatitis Secondary to Carbamazepine Treatment with Ursodeoxycholic Acid - A Case Report
Sabariah, Noor H.; Siti, Maisharah S.G.; Nor, Aizal C.H. & Khan, Amer Hayat


Background: Drug-induced hepatitis and several features of liver toxicity associated with the administration of carbamazepine have been reported; they involve non-immunoallergic hepatotoxicity and immunoallergic hypersensitivity syndrome. Ursodeoxycholic acid (UDCA) has liver protective effects and is indicated for hepatitis.
Case: An 18-year old patient with epilepsy and on carbamazepine 200 mg once daily was admitted to a hospital for generalised rash and significant elevation of liver enzymes. Carbamazepine was discontinued and replaced with leviteracetam 250 mg twice daily. Patient had cholestatic features of liver damage and UDCA 500 mg twice daily was given for 2 weeks until liver enzymes normalized.
Conclusion: Ursodeoxycholic acid treatment could be an alternative treatment for patient with carbamazepine-induced hepatitis.

Carbamazepine; Drug-induced hepatitis; Liver damage Ursodeoxycholic acid; Leviteracetam

© Copyright 2014 - Tropical Journal of Pharmaceutical Research
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil